BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25266736)

  • 21. Correction: comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.
    Cancer Discov; 2015 Mar; 5(3):332. PubMed ID: 25691095
    [No Abstract]   [Full Text] [Related]  

  • 22. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
    Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
    Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability.
    Jäkel C; Bergmann F; Toth R; Assenov Y; van der Duin D; Strobel O; Hank T; Klöppel G; Dorrell C; Grompe M; Moss J; Dor Y; Schirmacher P; Plass C; Popanda O; Schmezer P
    Nat Commun; 2017 Nov; 8(1):1323. PubMed ID: 29109526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathology and genetics of pancreatic neoplasms with acinar differentiation.
    Wood LD; Klimstra DS
    Semin Diagn Pathol; 2014 Nov; 31(6):491-497. PubMed ID: 25441307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusion genes in pancreatic tumors.
    Gkountakos A; Singhi AD; Westphalen CB; Scarpa A; Luchini C
    Trends Cancer; 2024 May; 10(5):430-443. PubMed ID: 38378317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
    Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.
    Klempner SJ; Bordoni R; Gowen K; Kaplan H; Stephens PJ; Ou SH; Ali SM
    JAMA Oncol; 2016 Feb; 2(2):272-4. PubMed ID: 26562024
    [No Abstract]   [Full Text] [Related]  

  • 30. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.
    Lu H; Villafane N; Dogruluk T; Grzeskowiak CL; Kong K; Tsang YH; Zagorodna O; Pantazi A; Yang L; Neill NJ; Kim YW; Creighton CJ; Verhaak RG; Mills GB; Park PJ; Kucherlapati R; Scott KL
    Cancer Res; 2017 Jul; 77(13):3502-3512. PubMed ID: 28512244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a novel B-Raf fusion protein related to c-Met drug resistance.
    Dillon R; Nilsson CL; Shi SD; Lee NV; Krastins B; Greig MJ
    J Proteome Res; 2011 Nov; 10(11):5084-94. PubMed ID: 21936566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
    Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
    Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.
    Lewis BC; Klimstra DS; Varmus HE
    Genes Dev; 2003 Dec; 17(24):3127-38. PubMed ID: 14681205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas.
    Kumar A; Pathak P; Purkait S; Faruq M; Jha P; Mallick S; Suri V; Sharma MC; Suri A; Sarkar C
    Cancer Genet; 2015 Mar; 208(3):91-5. PubMed ID: 25794445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.